These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9236947)

  • 21. Clinical evaluation of global change in Alzheimer's disease: identifying consensus.
    Olin JT; Schneider LS; Doody RS; Clark CM; Ferris SH; Morris JC; Reisberg B; Schmitt FA
    J Geriatr Psychiatry Neurol; 1996 Oct; 9(4):176-80. PubMed ID: 8970010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ADCS Prevention Instrument Project: behavioral measures in primary prevention trials.
    Cummings JL; Raman R; Ernstrom K; Salmon D; Ferris SH;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S147-51. PubMed ID: 17135808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proxy-rated quality of life in Alzheimer's disease: a three-year longitudinal study.
    Vogel A; Bhattacharya S; Waldorff FB; Waldemar G
    Int Psychogeriatr; 2012 Jan; 24(1):82-9. PubMed ID: 21729415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.
    Sano M; Zhu CW; Whitehouse PJ; Edland S; Jin S; Ernstrom K; Thomas RG; Thal LJ; Ferris SH;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S191-202. PubMed ID: 17135812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease.
    Zubenko GS; Zubenko WN; McPherson S; Spoor E; Marin DB; Farlow MR; Smith GE; Geda YE; Cummings JL; Petersen RC; Sunderland T
    Am J Psychiatry; 2003 May; 160(5):857-66. PubMed ID: 12727688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
    Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
    Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study.
    Holthoff V; Ferris S; Gauthier S; Ihl R; Robert P; Winblad B; Sternberg K; Tennigkeit F;
    Int J Geriatr Psychiatry; 2013 Feb; 28(2):164-72. PubMed ID: 22492589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.
    Tariot PN; Mack JL; Patterson MB; Edland SD; Weiner MF; Fillenbaum G; Blazina L; Teri L; Rubin E; Mortimer JA
    Am J Psychiatry; 1995 Sep; 152(9):1349-57. PubMed ID: 7653692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Noncognitive symptoms in Alzheimer's disease. A study of 150 community-dwelling patients using a questionnaire completed by the caregiver].
    Derouesné C; Piquard A; Thibault S; Baudouin-Madec V; Lacomblez L
    Rev Neurol (Paris); 2001 Feb; 157(2):162-77. PubMed ID: 11283463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI).
    Walsh SP; Raman R; Jones KB; Aisen PS;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S170-8. PubMed ID: 17135810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials.
    Galasko D; Bennett DA; Sano M; Marson D; Kaye J; Edland SD;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S152-69. PubMed ID: 17135809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
    Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
    Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.
    Stern RG; Mohs RC; Davidson M; Schmeidler J; Silverman J; Kramer-Ginsberg E; Searcey T; Bierer L; Davis KL
    Am J Psychiatry; 1994 Mar; 151(3):390-6. PubMed ID: 8109647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease.
    Back-Madruga C; Boone KB; Briere J; Cummings J; McPherson S; Fairbanks L; Thompson E
    Clin Neuropsychol; 2002 Aug; 16(3):331-40. PubMed ID: 12607146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical progression of moderate-to-severe Alzheimer's disease and caregiver burden: a 12-month multicenter prospective observational study.
    Agüera-Ortiz L; Frank-García A; Gil P; Moreno A;
    Int Psychogeriatr; 2010 Dec; 22(8):1265-79. PubMed ID: 20849672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.